In recent years, the oncogenic effects of phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling in cancer, including in endometrial carcinoma, have received increasing recognition (14, 15). This evidence concerns the gene MTOR and cancer.